The second largest drug selling company, Bristol-Myers Squibb is all set for optimistic targets for year 2013. After achieving better than expected earnings, the company seems overwhelmed and has pre-defined its milestones and goals for 2013 after taking the investors into confidence, after the Plavix patent.

The company is banking upon its major assets, which are expected to roll by 2012, namely Onglyza diabetes medicine and others.

It is bracing for steep revenue declines once generic competition hits Plavix, a blood-clot preventer. Bristol expects 2013 profits will drop by as much as 13 percent compared to this year.

According to the analyst Jon LeCroy, Hapoalim Securities, the shares of the company soared to 0.5 percent after the future guidance. Further, he stated that the upcoming medicines, straight from the drug seller might count on aggressive note.

Amidst the strong competition and the volatile environment, the company has made major cost cutting implication in its planning, and divested from the major shares and indeed has put money into smaller projects if it wishes to.

The shares of the company were trading strong, at 11.1 times the earnings, nearly 10 percent moving ahead from Arca Pharmaceutical index.

The group predicted the 2013 earnings, excluding items, by bare minimum of $1.95 per share. This shall reflect the potential decline a maximum of 13.